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1. Introduction 
Apolipoprotein H (ApoH), also known as beta2-glycoprotein I (ß2-GPI), is a plasma 
glycoprotein of 50 kDa. ApoH is present in human plasma at a concentration of between 150 
and 300 mg/ml (Bouma et al., 1999). In blood, ApoH circulate in free conformations or 
bound to lipoproteins: chylomicrons, very low-density lipoprotein (VLDL), low density 
lipoprotein (LDL) and high-density lipoprotein (HDL). In addition, ApoH has a high affinity 
for triglyceride-rich lipoproteins. The amount of ApoH associated with plasma lipoproteins 
in healthy individuals varies according to the authors from 4 to 13% (Gambino et al., 1999a) 
up to about 40% (Polz & Kostner, 1979). ApoH is able to activate lipoprotein lipases (Lee et 
al., 1983). ApoH was isolated from the fraction of plasma lipoproteins, and described for the 
first time in 1961 by H. Schultze E (Schultze, 1961). In a lesser extent, ApoH is also 
associated to ß2-globulin fraction.  
ApoH is expressed in human liver, in intestinal cells and tissues (Averna et al., 1997). In rats, 
other sites of synthesis in low concentrations were identified as the kidney, small intestine, 
brain, cardiomyocytes of the heart, and at even lower in the spleen, stomach and prostate 
(Ragusa et al., 2006). 
ApoH is an acute phase protein and because when activated, ApoH bind, with a relative 
high affinity, to pathogens or their proteins, ApoH is also considered as an element of the 
host innate immune response, particularly during the acute phase. It is difficult to classified 
as positive or negative acute phase protein. This property is used as a mean to drastically 
improve diagnostic of pathogens from different origins, including human, animal or 
environmental and nature, including enveloped or non-enveloped viruses, parasites, and 
Gram+ or Gram – bacteria. Indeed, activated ApoH coupled to solid supports is used to 
concentrate and “clean” pathogens (from inhibitor of detection methods) to detect 
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pathogens with molecular or immunological methods and thus avoiding false negative 
diagnostics.  
2. ApoH expression 
2.1 Structure and localization of the ApoH gene  
The gene encoding ApoH was localized by fluorescent in situ hybridization, on chromosome 
17, locus q23-24, and extends over 18 kilobases (kb). It consists of eight exons (~ 1.2 kb) 
separated by large introns (~ 16.2 kb) encoding a protein of 345 amino acids (aa). This 
protein is subsequently cleaved at a signal peptide of 19 aa located at the N-terminal 
position (N-ter) to generate the matured protein (Mehdi et al., 1991; Steinkasserer et al., 
1991). 
Eight exons will form the matured protein constituted of five domains. Exon 1 encodes the 
5'-untranslated region (5'-UTR) and the signal peptide. Exons 3 and 4 encode the domain II 
and exons 2, 5, 6 and 7 respectively encode domains I, III, IV and V of the protein. Exon 8 
encodes the C-terminal (C-ter), the stop codon and 3'-UTR region (Fig. 1) (Okkels et al., 
1999). 
 
 
Fig. 1. ApoH gene organization (Sodin-Semrl & Rozman, 2007) 
2.2 Promoter of the ApoH gene 
Using the HepG2 liver cell line, deletion analyses in the 5' region of ApoH gene evidenced 
that its promoter is located between positions -197 and 7 (Wang & Chiang, 2004). The ApoH 
gene expression is governed by several transcription factors including a liver-specific 
atypical TATA box (TATTA) located between positions -97 and -92 and the transcription 
factor HNF-1 (Hepatic nuclear factor-1) located upstream of the TATTA box. The soluble 
transactivation factor HNF-1ǂ interacts with HNF-1 leading to transactivation of the ApoH 
promoter. The gene expression increasing of endogenous ApoH is correlated with an 
overproduction HNF-1ǂ. 
Several transcription factors are able to bind multiple ApoH regulating sites. In liver cells, 
these sites are located near the promoter (up-670pb), as shown in Fig. 2. These transcription 
factors are: 
- STAT Signal Transducer and Activator of Transcription. 
- Leucine zipper domains: CREB (cAMP Response Element Binding) and C /EBPǃ 
(CCAAT-Enhancer-Binding Proteins).  
- AP-1 (Activating Protein 1) also known as TPA-responsive element (TRE) 
- HNF-3ǃ (Hepatocyte Nuclear Factor 3ǃ) involved in embryo development  
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- HNF1 (Hepatocyte Nuclear Factor 1), a transcription factor that regulates the expression 
of several hepatic proteins, including serum albumin or ǂ1-antitrypsin. 
- The protein NFAT (nuclear factor of activated T-cells) activated in the cytoplasm by 
calcium-dependent phosphatase. The signal may interact with transcription factors AP-
1 and NF-AT. 
 
 
Fig. 2. Promoter region of the ApoH gene and transcription factors (Wang & Chiang, 2004). 
The transcription sites in the promoter (TATA and CAAT boxes) are located near the 
initiation of ApoH transcription site (+1). Regulatory sites (blue), CAAT &TATA boxes 
(green), initiation site of transcription (red). 
2.3 Protein structure of ApoH 
Primary structure and domain concepts 
The peptide sequence of ApoH was identified in 1984. Its primary structure consists in a 
single polypeptide chain of 326 amino acids. With the exception of collagen and other 
related molecules, ApoH appears as one of the richest eukaryotic structures containing 
prolins, exhibiting 31 prolin residues per molecule. ApoH is also rich in lysin (30 residues), 
glycin (23 residues) and cystein (22 residues) (Lozier et al., 1984) amino-acids. 
The peptide sequence can be divided into four continuous domains of about 60 amino acids 
each, called SCR (short consensus repeat) and a fifth domain in the C-ter region (Lozier et 
al., 1984; Steinkasserer et al., 1991). SCR domains are also known under the term of Sushi 
domain, or CCP (Complement Control Protein) that are motifs often found in proteins of the 
complement system, but also in some proteins, such as interleukin-2 receptor. These SCR 
confer to the ApoH sequence exhibit a homology with several proteins such as VCP 
(vaccinia virus protein), CD46 (binding protein of measles virus) and HI, a Drosophila 
protein that belongs to the family of immunoglobulins and complement proteins. As shown 
in Fig. 3, each SCR contains four cysteins associated by pairs, Cys-1 to Cys-3 and Cys-2 to 
Cys-4 linked by disulfide (S-S) bridges (Okkels et al., 1999) that confers a high structural 
stability to ApoH.  
In contrast, the domain V of ApoH exhibits a very different structure. A sequence of six 
amino-acids (KNKEKK) is inserted within a highly positive charged region, an extension of 
19 residues at the C-ter and the presence of an additional S-S bridge (Steinkasserer et al., 
1991). A highly conserved tryptophan within the domain V will contribute to hydrophobic 
interactions with the ApoH partners. 
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Fig. 3. Alignment and organization of the disulfide bonds of ApoH (Steinkasserer et al., 
1991). 
Secondary structure of ApoH 
ApoH contains four N-glycosylation sites and one site of O-glycosylation linked to domain 
III and IV of the protein (Fig.4A). The glycosylated chains of ApoH are composed of 
galactose, mannose, N-acetylglucosamin, fructose, N-acetylneuraminic acid and sialic acid 
(Kamboh et al., 1988). They are linked to the peptide sequence via a nitrogen or oxygen atom 
(Gambino et al., 1999b).  
Secondary structures of each domain are composed of several anti-parallel beta-sheets, 
shorts, and coiled around a hydrophobic core (Fig. 4B). Two S-S bridges, respectively 
located in N-ter and C-ter stabilize the structure. A long central ß-sheet is framed along of 
the longitudinal axis by short beta-sheets parallels anti-parallels located near the C-ter and 
N-ter. The fifth domain, folds into a central ǃ -sheet composed of four anti-parallel ǃ-sheets 
and two short ǂ-helices and this domain is stabilized by three S-S bridges (Fig. 4C) (Bouma 
et al., 1999). 
 
 
Fig. 4. The different structures of glycosylated chains of ApoH (Gambino et al., 1997) 
Composition and organization of sugar chains 
There are three possible structures for the glycosilated chains (Fig. 5) (Gambino et al., 1997): 
Complex, hybrid and Mannose-rich. These structures have a common motif consisting in 
two N-acetylglucosamins and three mannoses, differing in the antennas composition, and 
their number varies from two to five. 
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Fig. 5. Structural representation ApoH and domains (Bouma et al., 1999). (A) Secondary 
structure ApoH; (B) Secondary structure of domain III of ApoH; (C) Secondary structure of 
domain V of ApoH. 
The ApoH inter-domain regions  
Different ApoH domains are linked each other by sequences respectively composed of three 
amino-acids, between domains IV and V, and four amino-acids for other domains. Between 
domains II-III and III-IV residues form chains of ǃ-sheets connecting the N-ter-B5 B4' sheet 
at the C-ter-sheet B1' B2'. The inter-domain represents 10-15% of the molecular surface. The 
inter-domain orientation varies in its inclination angle, ranging from 128 to 160° and a 
rotation angle ranging from 41 to 137°. Within the conserved domains, all are obtuse angles 
ranging from 120 to 162°, while the rotation angles vary widely between 22 and 180 ° 
(Bouma et al., 1999). 
Tertiary structure 
The analysis of crystallized structure of ApoH revealed a spatial organization to form a "J" 
or fishhook-like shape (Bouma et al., 1999; Schwarzenbacher et al., 1999). The four SCRs are 
arranged along a single axis with a slight spiral to the right to join the domain V. This very 
compact form suggests a certain rigidity of the protein. The X-ray analysis shows that in 
solution, the protein is folded, bulkier and exhibiting an “S-shape” (Fig. 6) (Hammel et al., 
2002).  
These differences may be explained by the absence of sugar chains in the crystallized 
protein and by changing the orientation of different domains due to the use of ions to form 
the crystal.  
 
 
Fig. 6. The ApoH structure (Hammel et al., 2002). Crystal form (left) compared with the 
schematic atomic structure model in solution (right). 
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However, recent studies on electronic microscopy has evidenced the presence of inactive 
ring forms of ApoH as well as the fishhook-like active ApoH able to catch LPS present in 
sepsis cases (Agar et al., 2011). 
3. ApoH and physiology 
The role of ApoH in vivo remains only partially elucidated. Studies conducted in vitro have 
demonstrated that ApoH has the particularity to bind, not only to negatively charged 
molecules and structures, including anionic phospholipids (PL), but also binds platelets, 
apoptotic cells (d'Angeac et al., 2005), mitochondria, DNA as well as bile acids (Schousboe, 
1983). Apart from the PL, ApoH also has the ability to bind cellular proteins such as the 
kidney calmodulin (Rojkjaer et al., 1997), megalin, an endocytic receptor of the renal 
epithelium (Moestrup et al., 1998), Annexin II (Ma et al., 2000) as well as other binding 
proteins or receptors including phosphatidylserine PS , LPS (Agar et al., 2011) and TLR2 
(Alard et al., 2010).  
Expression studies in HepG2 cells demonstrate that ApoH mRNA is regulated in a cell 
cycle-dependent manner, with very low expression in low cycling conditions and increasing 
levels in proliferating cells. p21 WAF-dependent growth arrest, induced by butyrate 
treatment, down-regulate ApoH mRNA levels. Immunolocalization in normal rat liver 
shows a non-homogeneous pattern, being mainly present in the centrolobular area; post-
hepatectomy regenerating rat liver is uniformly immuno-stained and mitotic elements show 
the highest protein expression. Albumin gene expression, studies as control liver specific 
product, was not affected by sodium butyrate induced growth arrest. As previously 
reported for endothelial cells, ApoH behaves as survival factor for HepG2 cells: when 
increasing amounts of the protein (10–50 μg) have been added to serum deficient cultured 
liver cells a progressive reduced cell loss was observed (Averna et al., 2004). 
In some autoimmune diseases, such as anti-phospholipid syndrome (APS), anti-ApoH 
antibodies and the complex ApoH-PL has been reported. These antibodies impact the 
inhibition of coagulation. They are associated with clinical manifestations of thrombotic 
venous or arterial type and recurrent fetal loss (Asherson & Cervera, 1993; Kandiah et al., 
1998). Thus, APS may be associated with various clinical manifestations: thrombocytopenia, 
coronary or valve damage, neurological disorders, and autoimmune hemolytic anemia. The 
presence of these antibodies may also occur in infectious diseases (viral, bacterial or 
parasitic) and neoplasia (solid tumors, lympho-proliferative disorders)(Arnoux & Boutière, 
2006; Harel et al., 2005). 
ApoH is also involved in the whole process of hemostasis regulation. ApoH inhibits both 
the factor Xa genesis, in the presence of platelets and the activation of factor XI (Shi et al., 
2005; Shi et al., 2004), as well as fibrinolysis, by preventing the generation of plasmin 
(Yasuda et al., 2004). ApoH also inhibits activated protein C that is an inhibitor of 
hemostasis (Keeling et al., 1993). ApoH therefore, exhibits both procoagulant and 
anticoagulant activities (McNeil et al., 1990). 
The presence of antibodies to form an immune complex ApoH consisting in ApoH-oxidized 
LDL:anti-ApoH antibodies, complex that is phagocytized by macrophages. Thus, there 
would be presentation of ApoH epitopes, by major the histocompatibility complex type II 
(MHC II), at the macrophages surface, leading CD4+ T cells activation. Moreover, it follows 
an excessive of macrophage lipids burden, and these macrophages are transformed into 
foam cells, the early stage of plaque formation. 
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Thus, ApoH is highly present in atherosclerotic plaques (George et al., 1999). ApoH allow 
binding and internalization of LDL in macrophages because of its ability to bind to LDL and 
oxidized LDL (Kochl et al., 1997). Moreover, ApoH is involved in apoptosis by binding to 
phosphatidylserine (PS), present at the surface of cells undergoing apoptosis (d'Angeac et 
al., 2005). Altogether, these data contribute to characterize ApoH as a scavenger-like protein. 
Finally, ApoH is also necessary to placental homeostasis and is involved in activation of 
endothelial cells and apoptotic mechanisms (Miyakis et al., 2004). However, despite 
available data showing pleitotropic functions of ApoH, many precise physiological roles of 
ApoH remain to be elucidated. 
The high correlation between ApoH and CRP expression during systemic inflammation 
indicates that ApoH is a part of the group of acute phase proteins (Sellar et al., 1993). 
However, the expression of the acute phase protein, ApoH, sometimes is upregulated and 
sometimes is down regulated, reflecting its pleiotropic functions Then, it become difficult to 
classify this APP as positive or negative. Indeed, divers data are sometime contradictory 
such as the observation of ApoH reduction in CSF during cerebral malaria (Agar et al., 2011) 
and the increase of ApoH in several other infectious diseases (Gast et al., 2006; Myles et al., 
2003; van Hemert et al., 2006).  
Due to different results presented here, ApoH can be considered as one of the major 
elements of the first line of the innate immune response regulating homeostasis.  
4. Interactions between ApoH and phospholipids  
ApoH has a strong ability to bind anionic phospholipids (PL), such as cardiolipin or 
phosphatidylserine, rather than the neutral PL, such as phosphatidylcholin (Wang et al., 
1998; Willems et al., 1996; Wurm, 1984). This interaction is ionic strength-dependent.  
 
 
Fig. 7. Binding between ApoH and membranes (Bouma et al., 1999). (A) Representation of 
the electrostatic potential ApoH surface, with a view rotated 180 °. ApoH domains are 
numbered from I to V. negative charges (red); positive charges (blue); (B) Prominent 
representation of half of the domain V. The positive charges are mainly due to the presence 
of lysine; negative charges (red), positive charges (blue); (C) scheme of the binding between 
ApoH (including the Tryptophan from domain V) and phospholipids bilayer. 
C 
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Mechanisms of interaction between the anionic PL and ApoH could involve two types of 
bonds: (i) ionic and (ii) hydrophobic, this latter involving the V domain of ApoH (Hammel 
et al., 2001; Wang et al., 1998). Initially, the sequence C-C-KNKEKK 281-288, highly 
positively charged (Steinkasserer et al., 1991), and most likely exposed on the surface of the 
protein would be responsible for the initiation of ionic bonds with anionic heads responsible 
for PL. A second step, would involves the insertion of a mobile hydrophobic loop of the 
protein in the PL layer (Fig. 8). The authors report a sort of anchor protein to the interface 
head polar/non-polar tail of PL via the hydrophobic (tryptophan) residue of the mobile loop 
region located in the position 311-SSLAFWK-317 (Hong et al., 2001; Mehdi et al., 2000). 
5. ApoH-viruses binding 
Enveloped and non-enveloped viruses  
Human and animal viruses such as influenza have a lipid bilayer coat covering their capsid, 
which is a protein box protecting the nucleic acid (short or large RNA or DNA). These 
envelopes are derived from portions of the host cell membranes including phospholipids 
together with specific viral glycoproteins that frequently mature during virus development. 
These glycoproteins play a pivotal role in the cell entry of these viruses. The cell entry of the 
non-enveloped viruses is less well known. However, for some viruses, such as for 
rotaviruses A, trypsin plays a role in preparing the capsid to find a good “conformation” of 
some peptides to fuse with the cell membrane to enter cells.  
6. The use of ApoH for drastic improvement of viral detection 
An interesting feature of ApoH, is its ability to bind both enveloped and non-enveloped 
viruses. Thus, it was shown that the protein bind hepatitis B virus (HBV), and more 
particularly the surface antigen HBsAg (Mehdi et al., 1994). HBsAg exists in three molecular 
forms: S for small, small protein, M for middle, moderate protein and L for Large protein 
(Fig. 9). The viral anionic PL are also involved in the interaction between ApoH and HBsAg 
(Neurath & Strick, 1994; Stefas et al., 2001). These results are reinforced by the fact that the 
recombinant HBsAg protein and anionic PL share the domain V of ApoH as binding 
domain (Mehdi et al., 2008). When viral PL becomes oxidized, the binding affinity ApoH-
HBsAg increases. It has been shown that ApoH has an affinity for infectious Dane particles  
 
 
Fig. 8. Structure of hepatitis B virus (http://dicos.ens-
lyon.fr/vie/viro/image/V05_2H1_Hepatites_8HBV.jpg) 
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that are characterized by the presence of a myristyl group on the pre-S1 domain of protein 
L. The presence of the myristyl group enhances its binding with ApoH (Stefas et al., 2001). 
Among experiments carried out by us, four HBV/HBsAg and HBV-DNA–positive patients’ 
sera were preincubated for 1 hr at 37°C in the presence or absence of 100 g/mL of 
polymyxin B or 2 mmol/L of iron or a mixture of both. The ability of HBV+ from patient 
sera (diluted at 1/100) to bind to ApoH-coated ELISA wells was assessed in the following 
conditions: sera HBV+ alone, in the presence of either polymyxin B (PB) or in the presence 
of Fe3+. ApoH–coated wells preincubated with PB or Fe3+ and washed were used as 
controls (Fig.9).  
 
 
Fig. 9. Effects of polymyxin B and/or metal ions on the ApoH–HBsAg binding.  
The preincubation of HBV+ sera with PB significantly reduced HBV/HBsAg binding to 
ApoH and this interaction was dose-dependent (data not shown). In contrast, the 
preincubation of HBV sera with Fe3+ increased HBV/HbsAg binding. No effect was 
observed when ApoH–coated wells were preincubated with polymyxin and washed, before 
the addition of serum. These data strongly suggest that viral phospholipids are involved in 
the ApoH–HBV/HBsAg interaction. 
It has been also shown that ApoH interact with antigens of human immunodeficiency virus 
(HIV) types I and II, particularly the Gag proteins of HIV 1 and 2 of p18 and p26 of HIV-1 
HIV-2 or of gp160 of HIV-1 (Stefas et al., 1997), suggesting that the interaction of ApoH with 
HIV proteins may result in part from the ApoH affinity for PL. According to Stefas et al. 
(1997), experimental conditions, such as acidic pH and/or the presence of detergent, could 
lead to conformational changes of ApoH or viral proteins thereby inducing the binding 
between ApoH and HIV-1. 
More recently, within the European USDEP project (www.usdep.eu), it has been shown that 
ApoH capture viruses including Hantavirus in both serum and urine from infected patients 
(Godoy et al., 2009), and very interestingly avoiding false negative generated by 
conventional and standard PCR methods (Fig. 10) and from stools rotavirus–infected 
patients permitting a very highly immune detection as sensitive as quantitative PCR 
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(Adlhoch et al., 2011). Within the same project, many other viruses have been shown 
strongly bind to ApoH, including poxvirus virus, hepatitis C virus, pseudorabies virus, 
vesicular stomatitis virus, and Altogether these data clearly demonstrate that ApoH binds 
enveloped or non-enveloped DNA or RNA virus with high affinity permitting their 
ultrasensitive detection.  
 
 
Fig. 10. ANDV binds serum-purified human ApoH (Godoy et al., 2009). Serum from 
patients S1 and S2 were tested for the presence of anti-hantavirus IgM (A) and IgG (B) 
antibodies by SIA using affinity-purified recombinant ANDV and Seoul virus N antigen. As 
internal controls, two levels (+1 and +3) of human IgG were applied to the blot. Serum from 
a negative donor (-) and of from a known HCPS-positive patient (+) were used as controls. 
Coomassie blue (CB) was used to determine the orientation of the strip. (C) Serum samples 
from patients S1 and S2 were divided in two. RNA was directly extracted from 300 µL of 
sample one without the addition of ApoH beads [(-) B; lanes 5 and 8]. In parallel, the second 
sample of each patient was submitted to an additional step of ANDV capture by ApoH-
coated magnetic beads prior to RNA extraction [(+) B; lanes 6 and 9]. Extracted RNA was 
used as the template in a RT-PCR/heminested PCR assay. As an additional control, total 
RNA extracted from sera of healthy negative donors with [(-) SC (+) B; lane 2] or without [(-) 
SC (-) B; lane 1] a step of virus capture and concentration by ApoH-coated magnetic beads 
was used as the negative control. Water controls for the RT-PCR (C1; lane 3) and heminested 
PCR (C2; lane 4) were included. In vitro-transcribed RNA corresponding to the ANDV S 
segment was used as a positive control for RT-PCR (HV RNA; lane 7). The arrow indicates 
the expected amplicon. 
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7. ApoH and bacteria relationship 
Circulating anti-ApoH antibodies in APS and infections 
In addition to circulating anti-ApoH antibodies in serum of patients exhibiting APS, an 
increased amount of anti-ApoH antibodies is also associated with several bacterial infections 
including: (i) urinary tract bacterial infections (Stojanovic et al., 2004); (ii) presence of 
Helicobacter pylori associated to ulcers (Pellicano et al., 1999); (iii) bacteria-associated 
rheumatic fever (Blank et al., 2004) and some other infections summarized in Table 1. 
 
Infection agents or pathology Frequency (%) 
Typhus 20 
Mycobacterium leprae 33 – 67 
Mycobacterium tuberculosis 27 – 53 
Bacterial endocarditis 5 – 44 
Helicobacter pylori ND 
Mycoplasma pneumoniae 20 – 53 
Staphylococcus aureus 43 
Streptococcus epidermidis 80 
Staphylococcus pyogenes 0 – 80 
Salmonella typhi 60 
Escherichia coli 67 
Coxiella burnetti 42 – 84 
Leptospirosis 50 
Borrelia burgdorferi 14 – 41 
Sacharomyces cerevisiae ND 
Plasmodium falciparum 30 
Table 1. Prevalence of anti-ApoH in infection associated diseases (Blank et al., 2004). *ND= 
undetermined 
Moreover, it was shown that epitopes recognized by the anti-ApoH antibodies, exhibited 
similarities with peptides associated to several infectious diseases (Blank et al., 2002; 
Gharavi et al., 2002). The ApoH-like epitope expressed by microorganisms, might use by 
these latter to escape the immune response via molecular mimicry mechanisms. Thus, 
pathogen ApoH-like epitope expression could induce autoimmune response. The 
involvement of molecular mimicry in the induction of APS was demonstrated in a mouse 
experimental model. Balb/c mice immunized with pathogens having sequence homology 
with the peptide TLRVYK, a peptide recognized by anti-ApoH. The mouse anti-TLRVYK 
Ab were purified and injected into new BALB/c, which have subsequently developed an 
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experimental APS (Blank & Shoenfeld, 2004). Synthetic peptides corresponding to the 
ApoH-phospholipid binding site and having a high sequence homology with 
cytomegalovirus, adenovirus and Bacillus subtilis were used to induce an APS (Gharavi et 
al., 2002; Gharavi et al., 1999). 
Changes of ApoH amounts have been reported in some bacterial infections. In a rare clinical 
case showing that a purpura fulminans phenomenon following an infection with Haemophilus 
influenzae in an adult was associated to a drastic elevation of the ApoH plasma concentration 
(Gast et al., 2006). A gene expression study performed on Helicobacter hepaticus-infected mice 
showed an increased expression of the gene of ApoH three months after infection, once a 
chronic inflammation was established (Myles et al., 2003). The infection of chickens with 
Salmonella leads to high ApoH gene over-expression approximately 40-fold excess as 
compared with uninfected controls (van Hemert et al., 2006). In contrast, it has been 
reported that Legionella pneumophila produces enzymes able to cleave ApoH (Muller, 1980).  
Altogether these reports suggest that increased gene expression of ApoH or even its 
"degradation" by enzymes induced by microorganisms may be in favor of active recognition 
of microorganisms by ApoH. 
Some ApoH-derived peptides have shown antibacterial effects against both Gram-positive 
(Staphylococcus pyogenes and S. aureus) and Gram-negative bacteria (Escherichia coli), while the 
intact entire ApoH protein did not exhibit any antibacterial effects. At the infection site, 
polymorphonuclear neutrophils (PMN) active secrete proteolytic enzymes. These enzymes 
generate antibacterial peptides derived from ApoH that can be found in high concentrations 
at the infected sites. These peptides bind to released bacterial cell wall and induce bacterial 
lysis (Fig. 11A). Thus, ApoH contributes as a precursor to the human innate immunity.  
However, it has been hypothesized that some bacteria, including S. pyogenes, may have 
developed defense mechanisms against the ApoH-derived peptides (Nilsson et al., 2008).  
 
 
Fig. 11. Mechanisms used by Streptococcus pyogenes AP1 to neutralize the effect of anti-
bacterial peptides derived from ApoH (Nilsson et al., 2008). (A) At the site of infection, 
activated neutrophils secrete proteolytic enzymes generating lytic antibacterial ApoH-
derived peptides. (B) Mechanisms proposed to be used by AP1 bacteria to prevent the 
antibacterial activity of ApoH: (i) The binding of ApoH to S. pyogenes surface proteins M1 
and H prevents the cleavage of the ApoH; (ii) soluble proteins M1 and H interact with 
ApoH-derived peptides to neutralize their anti-bacterial effects. 
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The first mechanism is the link between the bacterium and the ApoH. Once ApoH is bound 
to bacteria, proteinases from PMN cannot cleave ApoH and therefore the production of 
antibacterial ApoH-derived peptides is reduced (Fig. 11B1). The second mechanism 
circumventing host immune defenses is the binding of soluble proteins M1 and H with 
peptides derived from ApoH inducing the inactivation of these latter. The proteins M1 and 
H became soluble due to proteases from the PMN that cleaved proteins M and H of the 
bacterium surface (Fig. 11B2). 
Thus ApoH, a precursor of antibacterial peptides, would be a mechanism of host protection 
against infectious agents. It is possible to speculate that certain bacteria are capable to 
neutralize ApoH via their binding mechanisms and thereby escaping the host immune 
responses.  
General structure of bacteria 
Bacteria belong to one independent branch of the tree main phyla of life (Woese, 1987). 
Bacteria have characteristics that are not found in other living prokaryotes (Archeae) or 
eukaryotes. These are bacterial surface structures, which have the most unique features, not 
shared with other living beings. Among these structures, the bacterial wall, the 
exopolysaccharides, protein structures as external S layer, pili, flagella. Most of these surface 
structures are involved in bacteria-host interactions through their adhesion molecules at 
their surfaces with host’s cells. In addition, these interactions play a pivotal role in bacterial 
pathogenicity. 
Despite their simple morphology and unicellular organization, bacteria present both large 
organic and structural diversities. This structural diversity is primarily expressed in surface 
structures. Structure and function properties of the bacteria envelope structures of are a 
direct consequence of their adaptive strategies. 
Bacterial cell wall 
Bacteria cells are particularly robust because of their cell wall, which allow them to 
withstand particularly high variations in osmotic pressure. The wall structure is a base for 
the determination of major bacterial groups mainly including: Gram-positive bacteria, 
Gram-positive and mycobacteria. 
The common component of bacterial cell wall or murein is a peptodoglycane. Murein is a 
polymer of two sugar-derivatives (N-acetylglucosamin and N-acetylmuraminic) and several 
amino-acids and/or lipids that largely differ in a specie-depending manner. 
Gram-positive’s cell wall 
The wall of Gram-positive bacteria is a homogeneous structure with thickness variation 
from 10 to 80 nm. It consists mostly of a thick layer of multimolecular murein associated 
with lesser amounts of other dispersed polymers, especially the teichoic and teichuronic 
acids). 
There are a wide variety of these compounds being highly antigenic. The nature of their 
carbohydrate skeleton, and position of many substitutions are submitted to considerable 
variations. 
Numerous other components are also present in some species, such as proteins or 
polysaccharides, and they can play an important role in the antigenic properties or 
pathogenicity. For example, protein A, found in over 98% of strains of Staphylococcus aureus, 
is a receptor for the Fc fragment of immunoglobulin G that when present on bacteria surface 
will inhibits opsonization. In addition, bacterial mutants lacking protein A present a lower 
virulence in mouse experimental infections. 
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Gram-negative’s cell wall 
The wall of Gram-negative bacteria is more complex. We distinguish an inner membrane 
and outer membrane, which defines a periplasmic space containing a thin layer of 
peptidoglycan. The wall is much thinner than those of Gram-positive bacteria, of about 10 
nm. Murein of gram-negative bacteria does not contain teichoic acid. 
Periplasmic space contains the Braun lipoproteins, which connects the outer membrane to 
peptidoglycan involved in the cohesion of the wall. 
The outer membrane has a distinct chemical composition. Its structure is a phospholipid 
bilayer with the inner layer has a composition similar to that of the cytoplasmic membrane. 
Its outer layer, by cons, has a particular constituent embodiment in the PL: 
lipopolysaccharide (LPS) is a complex molecule consisting of three components: (i) The lipid 
A, which anchors the LPS in the outer leaflet of the outer membrane. This lipid A is also 
called endotoxin because of these properties highly toxic for the host. Endotoxin is 
responsible for septic shock in systemic infections with Gram-negative bacteria; (ii) short 
series of sugar in the center including: desoxyoctonoic keto-acid and heptose; (iii) long 
carbohydrate chain whose length is 40 sugars that constitutes the O antigen, covering the 
surface of the bacterium highly antigenic. 
The outer membrane also contains a large number of proteins such as porins involved in the 
permeability of small hydrophilic molecules (<600 Da) and proteins involved in bacterial 
virulence (http://www.bacterio.cict.fr/bacdico/bacteriogene/structure.html). 
7.1 Bacteria and ApoH binding 
In vitro direct interaction has been shown between S. aureus and ApoH via the Sbi protein 
(Zhang et al., 1999). Furthermore, a study from a DNA library of S. aureus phages and on 
human blood proteins that adhere to implanted materials, such as catheters, showed the 
presence of ApoH on these biomaterials. This study attest to the connection on the ex vivo 
biomaterial ApoH S. aureus (Bjerketorp et al., 2004). More recently (Agar et al., 2011), it has 
been shown that upon interaction of LPS with domain V of ApoH, a conformational change 
occurs in ApoH binds LPS from the  ring or close form to  a “J or fishhook-like form”. Thus, 
the ‘active’ fishhook-like conformation of ApoH in complex with LPS is then able to bind to 
the LPR receptor after which the ApoH-LPS complex is cleared (4). The scavenging of LPS 
by ApoH leads to a decreased binding of LPS to the TLR-4 receptor resulting in a decreased 
expression of the inflammatory markers TNFα, IL-6 and IL-8.  
ApoH also interacts with Streptococcus pyogenes. At least two streptococcal proteins are 
involved in this interaction, M1 protein and H factor, which are surface proteins. M1 protein 
is a virulence factor, allowing the bacteria to resist phagocytosis. The M1 protein would 
interact with plasma proteins (fibrinogen, C4b binding protein, H factor) to avoid bacterial 
lysis (Nilsson et al., 2008). 
7.2 The use of ApoH to drastic improvement of bacterial detection  
As different bacteria are able to interact with ApoH, we used these fundamental property to 
propose that ApoH can be a useful tool to capture, from different complex biological media, 
different kinds of bacteria (Gram- or Gram+) and proceed to their detection and/or 
diagnostic (Fig. 12) by using different methods including ATP detection by luminometry, 
cultivation in an appropriated media or PCR.   
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Fig. 12. Bacterial detection. (left) ATP detection and specific cultivation of Pseudomonas 
aeruginosa and Seratia marcescens from clinical hemocultivation; (right) 16S RNA PCR. 
Bacterial Luria broth (LB) Medium (1), ApoH-captured Escherichia coli from LB medium (2), 
positive PCR control, E. coli DNA (3), H2O (4) 
8. Conclusion  
Taking into account literature data and our own data, it is possible to mention that, probably 
one of the main roles for the acute phase protein ApoH is to be an important actor of host 
innate immune response through its capacity to bind with high affinity to a large panel of 
pathogens and or antigens from different origins. This ApoH property can be applied to face 
a tremendous public health problem that is the existence of (re)-emerging pathogens and 
their difficulties to be detected.  
Indeed, according to the Center for Disease Control and Prevention in Atlanta  (CDC), 70% 
of emerging infectious diseases in humans, are zoonotic pathogens. Most of theses human 
diseases are caused by the introduction of existing pathogens into human populations from 
other species or dissemination from endemic areas into larger populations. This process 
depends upon a complex interaction of factors such as ecological, environmental and/or 
climatic changes, the basic biology of pathogens, host and cell tropism, the route of 
transmission, the natural host reservoir and the vector, social behavior, international travel 
and commerce, political instability, breakdown in public health measures, etc.  
Nucleic acid amplification is widely used for the detection and identification of pathogens. 
Sequencing and comparison to known microorganisms may allow identification of 
unidentified pathogens.  Extraction and careful purification of DNA and/or RNA is an 
essential step for sensitivity and reliability of these diagnostic techniques, but often 
incompatible within high throughput screening in routine diagnostics eg. in blood 
transfusion centres where large series of samples have to be tested. Several major diagnostic 
companies have been involved in the development of universal viral nucleic acid 
purification systems from plasma and serum, compatible with IVD (In Vitro Diagnostics) 
assays. However, despite a gain in sensitivity brought by these methods, the EQA studies 
revealed that molecular diagnostics still showed a poor overall test proficiency compared to 
serological diagnostics. One of the main problems for pathogen detection in clinical but also 
in environmental samples is that they generate false negative results. This problem is mainly 
due to 3 reasons: 
i. Presence of inhibitors such as heme, anticoagulants like EDTA and heparin, high 
concentrations of leukocyte DNA, immunoglobulins and other unknown inhibitors of 
nucleic acid amplification in the plasma or serum (Al-Soud et al., 2000; Al-Soud & 
www.intechopen.com
 Acute Phase Proteins as Early Non-Specific Biomarkers of Human and Veterinary Diseases 
 
36
Radstrom, 2001; Wilson, 1997). Such an inhibition was described at a frequency of 0.34 to 
2.1% of tests for patients infected with human immunodeficiency virus type 1 or hepatitis 
C virus, respectively (Drosten et al., 2001; Nolte et al., 2001). In the case of patients with 
severe viral hemorrhagic fever false-negative results are also likely to occur, especially in 
the acute phase of the disease where a rapid confirmation is required for the introduction 
of countermeasures(Drosten et al., 2002). In this scenario it is extremely important to 
develop methods for pathogen concentration allowing their separation from these 
reaction inhibitors. Such a technology is critical for the development of novel 
methodologies of sample préparation which would result in the reliable detection of 
pathogens present within complex biological samples such as blood. 
ii. Absence of a universal extraction method that efficiently lyses the pathogens and allow 
the separation of nucleic acids (RNA or DNA) from other components of the 
microorganisms or cellular materials that might interfere with downstream processes. 
Different nucleic acid extraction techniques have shown to result in variable diagnostic 
outcome for viruses detected by the polymerase chain reaction (PCR). The choice of 
appropriate RNA and DNA extraction methods, thus, is a critical step for the successful 
and valid use of RT-PCR and PCR based exams on clinical samples (Fredricks et al., 
2005; Labayru et al., 2005; Scansen et al., 2005), 
iii. Lack of a rapid and reliable pathogen concentration methodology. Often pathogens 
present in clinical samples and particularly in environmental samples are diluted in 
large sample volumes poorly amenable for molecular methods (Brassard et al., 2005; 
Dreier et al., 2004; Fung et al., 2000); in this case, working with a small fraction of the 
sample may lead to false-negative results due to the specific sensitivity of the used 
detection method. Yet, simple and inexpensive methods for the concentration of 
pathogens, present within the samples, that could be easily introduced into the normal 
working scheme used by most clinical microbiology laboratories involved in the routine 
screening of large numbers of human samples are currently not at hand. 
One of the main concerns for pathogen detection in clinical, but also in environmental 
samples, is that they generate false negative results that are mainly due to: (i) presence of 
inhibitors, (ii) absence of suitable molecular detection methods (e.g. PCR) and (iii) lack of a 
rapid and reliable pathogen concentration methodology. 
The above-mentioned disadvantages have been compensated by the use of a matrix-bound 
ApoH to concentrate pathogens from biologically complex fluids (blood, feces, tissues, etc).  
After capture, washing of the ligand-pathogen(s) complex would allow removal of the 
inhibitors of the subsequent diagnostic steps.  Thus, in this novel diagnostic schema the 
concentrated pathogen(s) would be highly accessible to any subsequent method of 
extraction, thus increasing the expected efficiency and sensitivity of nucleic acid detection.  
Thus, ApoH-coated solid matrix is used as a generic capture method for a wide range of 
pathogens in order to concentrate them from large sample volumes of complex biological 
mixtures, otherwise poorly amenable for molecular methods and thus to improve their 
detection threshold (Fig. 13). 
Tools and protocols have been established to use this simple, fast and broad target method 
adapted to different types of specimen, saliva, plasma, serum, urine and feces as well as 
various environmental samples. Thus, the pre-analytical sample processing by ApoH allows 
an efficient and ultrasensitive detection of very divers pathogens from their originated 
media using simple or sophisticated methods related to immunological (ELISA) or 
molecular (real-time RT-PCR) detection techniques, therefore drastically diminishing false 
negative diagnostics generated by classical standardized method. 
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Fig. 13. A schematic representation of different steps to capture and concentrate 
microorganisms from complex biological fluids using ApoH-coated nano-magnetic beads to 
drastically improve their ultra-sensitive detection.  
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